Core Viewpoint - Opus Genetics, Inc. reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, marking an earnings surprise of -31.21% [1] Financial Performance - The company posted revenues of $3.87 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 47.07%, although this represents a decline from year-ago revenues of $4.3 million [2] - Over the last four quarters, Opus Genetics has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Opus Genetics shares have increased approximately 137.3% since the beginning of the year, contrasting with a 0.7% decline in the S&P 500 [3] - The current Zacks Rank for Opus Genetics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $3.21 million, and for the current fiscal year, it is -$0.45 on revenues of $15.77 million [7] - The estimate revisions trend for Opus Genetics was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Opus Genetics belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates